

Guidelines on Pericardial Diseases 2015 (TF18) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Adler Yehuda	Nothing to be declared (2013-2014-2015)
Badano Luigi Paolo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - SamsungMedison : Ultrasound (2013) - Edwards Lifesciences : Clinical Event Committee member (2013-2014) - Sorin Group : Consultancy (2013-2014) - GE Healthcare : Ultrasound (2013-2014-2015) - Edwards Lifesciences : Heart valve prostheses. Clinical Event Committee member (2015) - Sorin Group : Heart valve prostheses. Consultancy (2015) - Epygon : Start-up, bioprostheses. Advisory board (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Epygon : Heart valve prostheses (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - GE Healthcare : Ultrasound (2013-2014-2015) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - GE Healthcare : Ultrasound (2013)
Baron Esquivias Gonzalo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation (2013-2014-2015) - Boehringer-Ingelheim : Anticoagulation (2013-2014-2015) - Daiichi Sankyo : Anticoagulation (2013-2014-2015) - Pfizer : Anticoagulation (2013-2014-2015) - Menarini : Ischemic disease (2015) - Laboratorios Rovi : Ivabradine (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Biotronik : Vasovagal syncope & Pacing (2013) - Bayer : Anticoagulation (2015)
Bogaert Jan	Nothing to be declared (2013-2014-2015)

Guidelines on Pericardial Diseases 2015 (TF18) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Brucato Antonio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Menarini : hyperuricemia (2013) - Pharmintertrade sas : colchicine (2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - FAR.G.IM S.r.L : colchicine (2014) - ACARPIA : colchicine (2015)
Charron Philippe	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Heart failure and CAD (2013) - Shire HGT : Lysosomal diseases (2013-2014-2015) - Genzyme : Lysosomal diseases (2013-2014-2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Shire HGT : Fabry disease, Cardiomyopathies (2014)
Gueret Pascal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo, General Electric; Merck-Sharpe Dohme, Servier. : Myocardial ischaemia, hypertension, heart failure, cardiac imaging (2013-2014-2015) - Haute Autorité de Santé (France) : Pratiques professionnelles et Sécurité des soins (2013-2014-2015) - Correvio : anti thrombotic agents (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Société Française de Cardiologie : research funding (2013) - Fondation Coeur et Recherche : general cardiology. Research funding (2013-2014)
Imazio Massimo	<p>Nothing to be declared (2013)</p> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - UptoDate, Wolters Kluwer Health : Medical Publisher (2014-2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - SOBI : Anakinra and recurrent pericarditis (2014-2015) - Acarpia srl Madeira, Portugal : Colchicine and pericarditis (2014-2015) - FARGIM, Catania, Italy : Colchicine and pericarditis (2014-2015)

Guidelines on Pericardial Diseases 2015 (TF18) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Klingel Karin	<p>D - Research funding (departmental or institutional). - Novartis : Research on IL-1β in myocarditis (2013-2014-2015)</p>
Lionis Christos	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : Speaker fees (2013) - GlaxoSmithKline : Speaker fees (2013) - Pfizer Hellas : Speaker fees (2013) - Spring to Life Ltd : Teaching fees (2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Leo Pharma : consultancy fees (2014) - MSD : speaker fees (2014) - UCB : speaker fees (2014) - Vianex : speaker fees (2014) - APR : speaker fees (2014) - Pfizer International Operations : speaker fees (2014) - GlaxoSmithKline : teaching fees (2014)</p> <p>D - Research funding (departmental or institutional). - Pfizer : Community acquired pneumonia epidemiological research study. No product or therapeutic area. (2013)</p>
Maisch Bernhard	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Springer Company, Managing Editor of HERZ/Cardiovascular Diseases : Medical Review Journal (2013) - Springer Company : Honorarium as Editor of HERZ/Cardiovascular Diseases (2014) - Biotest company : i.v. Immunoglobulins (2015)</p>
Mayosi Bongani Mawethu	<p>Nothing to be declared (2015)</p> <p>D - Research funding (departmental or institutional). - Pfizer, Servier, and AstraZeneca : Heart Failure (2013)</p> <p>E - Research funding (personal). - Pfizer, Servier, and AstraZeneca : Heart Failure (2013)</p>

Guidelines on Pericardial Diseases 2015 (TF18) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Mayosi Bongani Mawethu	<ul style="list-style-type: none"> - Astra Zeneca : Heart Failure (2014) - Novartis : Rheumatic heart disease (2014) - Cadila Pharma : Tuberculous pericarditis (2014)
Pavie Alain	Nothing to be declared (2013-2014-2015)
Ristic Arsen	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Richter Gedeon : Hypertension, Angina pectoris (2013) - Teva Pharmaceutical Industries : Hypertension, Heart Failure (2013) - Merck Serono : Bisoprolol and combination therapy (2013-2014) - Abbott : Hypertension (2013-2014) - Servier : Angina pectoris, Heart Failure (2013-2014-2015) - Boehringer-Ingelheim : Novel oral anticoagulants (2013-2014-2015) - Astra Zeneca : Ticagrelor (2013-2014-2015) - Sanofi Aventis : Alirocumab clinical trial (2014-2015) - Roche Pharma : Cardio-renal interactions in diabetic patients (2014-2015) - Pfizer : Cardiovascular risk, Pulmonary hypertension (2014-2015) - Genzyme : Fabry disease (2014-2015) - Berlin Chemie AG : heart failure, arterial hypertension (2014-2015) - Krka Pharma : Hypertension (2015) - Hemofarm A.D. : Hypertension (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Ministry of Science and Education of the Republic of Serbia : Heart failure, Myocardial and Pericardial Diseases (2013-2014-2015) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Ministry of Science and Education of the Republic of Serbia : Heart failure, Myocardial and Pericardial Diseases (2013-2014-2015)

Guidelines on Pericardial Diseases 2015 (TF18) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Sabate Tenas Manel	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medtronic : stent (2013) - Abbott Vascular : Stent (2013-2014-2015)
Seferovic Petar	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : heart failure, hypertension (2013-2014-2015) - Pfizer : heart failure, hypertension (2013-2014-2015) - Berlin Chemie AG : heart failure, hypertension (2013-2014-2015) - Richter Gedeon : hypertension (2013-2014-2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Ministry of Science and Education of the Republic of Serbia : heart failure, myocardial and pericardial disease (2013-2014-2015)
Swedberg Karl	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Amgen : Heart Failure (2013-2014-2015) - Novartis : Heart Failure (2013-2014-2015) - Servier : Heart Failure (2013-2014-2015) - Vifor Pharma : Heart Failure (2013-2014-2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Amgen : Heart Failure (2013) - Servier : heart Failure (2013-2014-2015)
Tomkowski Witold Zbyszek	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer, Boehringer, Daichi Sankyo : thrombosis (2013) - Bayer : thrombosis (2014) - Portola Pharmaceuticals : Thrombosis (2015) - Aspen : Thrombosis (2015)

Guidelines on Pericardial Diseases 2015 (TF18) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Abaci Adnan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : Hypertension (2013) - Bristol Myers Squibb : Oral anticoagulation for atrial fibrillation (2013) - Menarini : Hypertension (2013-2014) - Astra Zeneca : Acute Coronary Syndrome (2013-2015) - Bristol Myers Squibb : Anticoagulation (2014) - Astra Zeneca : Antiplatelet (2014) - Pfizer : Atrial fibrillation (2015)
Aboleineen Mohamed Wafaie	<p>Nothing to be declared (2015)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : antihypertensive (2013-2014)
Achenbach Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation (2013) - Behring : Anticoagulation (2013) - Astra Zeneca : Antiplatelet Therapy (2013) - Abbott : Coronary Intervention (2013) - Siemens Healthcare : CT (2013) - Servier : Imaging (2013) - Guerbet : Imaging (2013) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Abbott : Coronary Intervention (2013-2014) - Siemens Healthcare : Imaging (2013-2015)
Agewall Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Böhringer Ingelheim : Anticoagulation treatment (2013) - Roche Diagnostics : Cardiac markers (2013)

Guidelines on Pericardial Diseases 2015 (TF18) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Agewall Stefan	<ul style="list-style-type: none"> - Orion : Heart failure (2013) - Pfizer : Lipids (2013) - Sanofi Aventis : Lipids (2013) - Siemens Healthcare : Markers (2013) - Astra Zeneca : Platelet inhibition (2013-2014-2015) - Thermo Fischer Scientific : Cardiac markers (2014-2015)
Al-Attar Nawwar	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Johnson & Johnson : haemostasis (2013-2014-2015)
Andersson Bert	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Heart failure (2013-2014-2015) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : Renal denervation (2014-2015) - Recor Medical : Renal denervation (2014-2015)
Angel Ferrer Juan	Nothing to be declared (2013-2014-2015)
Antov Slobodan	Nothing to be declared (2013-2014-2015)
Arad Michael	Nothing to be declared (2013-2014) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Genzyme : Fabrazyme (2015)
Archbold Andrew	Nothing to be declared (2013-2014-2015)
Arutyunov Grigory P	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Takeda Pharmaceuticals : Loop Diuretics (2013-2014-2015) - Berlin Chemie AG : Beta-blockers (2015) - Servier : If blockers (2015) E - Research funding (personal). - Takeda Pharmaceuticals : Loop Diuretics (2013-2014-2015)

Guidelines on Pericardial Diseases 2015 (TF18) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Asteggiano Riccardo	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Chiesi Pharma : Rosuvastatin (2013-2014) - Edwards Lifesciences : Prosthetic valves (2015)
Bouma Berto	Nothing to be declared (2013-2014-2015)
Bueno Hector	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - BMS/Pfizer : Apixaban (2013) - Roche Pharma : Dalcetrapib (2013) - Novartis : Relaxin (2013) - Bayer Healthcare : Aspirin, rivaroxaban (2013-2014-2015) - Sanofi Aventis : Clopidogrel (2013-2014-2015) - Daiichi Sankyo : Prasugrel (2013-2014-2015) - Eli Lilly : Prasugrel (2013-2014-2015) - Astra Zeneca : Ticagrelor (2013-2014-2015) - Novartis : Serelaxin (2014) - Pfizer : Apixaban (2014-2015) - Bristol Myers Squibb : Apixaban (2014-2015) - Servier : ivabradine (2014-2015) - Menarini : Ranolazine (2014-2015) - Abbott : Absorb stent (2015) - Novartis : Serelaxin, ACZ696 (2015) - Ferrer Internacional : Trinomia (polypill) (2015) D - Research funding (departmental or institutional). - Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015)

Guidelines on Pericardial Diseases 2015 (TF18) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bueno Hector	E - Research funding (personal). - Astra Zeneca : Ticagrelor (2013-2014-2015)
Caforio Alida L P	Nothing to be declared (2013-2014-2015)
Carerj Scipione	Nothing to be declared (2013-2014-2015)
Ceconi Claudio	Nothing to be declared (2013-2014-2015)
Codreanu Andrei	Nothing to be declared (2013-2014-2015)
Damy Thibaud	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Alnylam : Amyloidosis (2013-2014) - Free binding site : Amyloidosis (2013-2014) - Pfizer : amyloidosis, heart failure, pulmonary hypertesion (2013-2014) - Astra Zeneca : Heart failure (2013-2014) - Servier : Heart failure (2013-2014) - Sorin Group : Heart failure (2013-2014) - Vifor International : Heart failure and anemia (2013-2014) - Novartis : Heart failure and heart transplantation (2013-2014) - Resmed : Sleep apnea (2013-2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Pfizer : Amyloidosis (2013-2014) - Novartis : Cardiac transplantation (2013-2014) - Actelion : Pulmonary hypertension (2013-2014) - Resmed : Sleep apnea (2013-2014) - Pfizer : Amyloidosis and PAH (2015) - Daiichi Sankyo : Anticoagulant (2015) - Resmed : SDB (2015)

Guidelines on Pericardial Diseases 2015 (TF18) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Dimitriadis Kyriakos	Nothing to be declared (2013-2014-2015)
Dimulescu Doina Ruxandra	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : atrial fibrillation (2013) - Pfizer : atrial fibrillation (2013) - Bristol Myers Squibb : atrial fibrillation (2013) - Servier : Heart failure (2013) - Berlin Chemie AG : hypertension (2013) - Krka Pharma : hypertension (2013) - Zentiva : ischemic heart disease (2013) - Novartis : hypertension (2013-2014-2015) - Astra Zeneca : ischemic heart disease (2013-2014-2015) - Servier : Hypertension, heart failure (2014) - Pfizer : Anticoagulant therapy (2014-2015) - Boehringer Ingelheim : anticoagulant therapy (2014-2015) - Brigham and Women s Hospital : Antiplatelet therapy (2014-2015) - Sanofi Aventis : Dyslipidemia (2014-2015) - Romanian Society of hypertension : Hypertension (2014-2015) - Servier : antihypertensive therapy (2015) - Krka Pharma : antihypertensive therapy (2015) - Brigham and Women Hospital : antiplatelet therapy (2015) - Bayer : antithrombotic therapy (2015) - Boehringer-Ingelheim : antithrombotic therapy (2015) - Pfizer : antithrombotic therapy (2015)

Guidelines on Pericardial Diseases 2015 (TF18) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Dimulescu Doina Ruxandra	<ul style="list-style-type: none"> - Astra Zeneca : atherosclerosis (2015) - Sanofi Aventis : atherosclerosis (2015) - Labormed : atherosclerosis (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : ischemic heart disease (2013) - Sanofi Aventis : ischemic heart disease (2013) - Astra Zeneca : ANTIPLATELET THERAPY (2014) - Sanofi Aventis : Acute coronary syndrome (2014-2015) - Astra Zeneca : antithrombotic therapy (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - ANCS BIOMARCAD Trial : atherosclerosis (2015)
Dingli Philip	Nothing to be declared (2013-2014-2015)
Dubrava Juraj	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : ivabradine (2013-2014-2015) - Boehringer-Ingelheim : dabigatran (2014-2015) - Bayer AG : rivaroxaban (2014-2015)
El Hattaoui Mustapha	<p>Nothing to be declared (2015)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Pfizer : advisory board fees on APIXABAN (2013-2014)
Evangelista Masip Artur	Nothing to be declared (2013-2014-2015)
Flachskampf Frank Arnold	Nothing to be declared (2013-2014-2015)
Gatzov Plamen Marinov	Nothing to be declared (2013-2014-2015)
Giannakoulas George	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : Acute Heart Failure (2013-2014) - Astra Zeneca : Cardiovascular risk (2013-2014)

Guidelines on Pericardial Diseases 2015 (TF18) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Giannakoulas George	<ul style="list-style-type: none"> - Menarini : Chronic coronary artery disease (2013-2014) - Bayer : Pulmonary Hypertension (2013-2014) - Actelion : Pulmonary Hypertension (2013-2014) - Pfizer : Chronic Heart Failure, Atrial Fibrillation (2014) - Servier : Chronic coronary artery disease (2014-2015) - MSD : Hyperlipidemia (2014-2015) - Pfizer : Atrial Fibrillation (2015) - Astra Zeneca : Coronary artery disease (2015) - Bayer : Pulmonary Hypertension - Atrial Fibrillation (2015)
Gielen Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Lectures 2013 (2013) - Bayer Healthcare : Lectures 2013 (2013) - Novartis : Lectures 2013-14, Travel grant AHA (2013) - Boston Scientific : Lecture (2014) - Servier : Lectures 2013 (2014) - Novartis : Lectures 2014 (2014) - Astra Zeneca : Lecture/Chairperson 2014, Advisory Board (2014-2015) - Sanofi Aventis : Lecture, Travel Grant (2015) - Elixier : Travel Grant (2015)
Habib Gilbert	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : pulmonary hypertension (2013-2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Pfizer : pulmonary hypertension (2013-2014-2015) - Abbott : Mitraclip (2015)

Guidelines on Pericardial Diseases 2015 (TF18) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Habib Gilbert	<ul style="list-style-type: none"> - Actelion : Pulmonary Hypertension (2015) D - Research funding (departmental or institutional). - Genzyme : Fabry's disease (2015)
Heracleous Hera	Nothing to be declared (2013-2014-2015)
Hoffman Piotr	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott, Servier, Bayer, Actelion, General Electric, Polpharma, : cardiological drugs, echo machines (2013) - Abbott, Servier, Polpharma, Merck, MSD, Novartis, Amgen, Berlin-Chemie, General Electric, Actelion, Bayer, : cardiological drugs, echo machines (2014-2015)
Isayev Elnur	Nothing to be declared (2013-2014-2015)
Kavoliuniene Ausra	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : beta blockers use in CVD (2013) - Krka Pharma : ARBs - Speaker's fee (2013-2014-2015) - Berlin Chemie AG : BB - Speaker's fee (2013-2014-2015) - Servier : RCTs, Speaker's Fee (2013-2014-2015) - Bayer : Speaker's fee (2014) - Remedica : NOACs - Speaker's fee (2014-2015) - Bayer : Speaker's fee, Investigator fee (2015) D - Research funding (departmental or institutional). - Novartis : Serelaxin (2015) - Cardioentis : Ularitide (2015)
Kiss Robert Gabor	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : apixaban (2013-2014-2015) - Boehringer-Ingelheim : dabigatran (2013-2014-2015) - Bayer Healthcare : rivaroxaban (2013-2014-2015) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - TIMI group : steering committee member (2013-2014-2015)

Guidelines on Pericardial Diseases 2015 (TF18) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - B.Braun : Surgical instruments (2013-2014) - Astra Zeneca : Antiplatelet agents (2013-2014-2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - St Jude Medical : Cardiac valves (2013) - Boston Scientific : Coronary stents (2013) - Siemens Healthcare : Medical imaging (2013) - Johnson & Johnson : Thoracoscopic devices (2013) - Edwards Lifesciences : Cardiac valves (2013-2014-2015) - Medtronic : Cardiac valves (2013-2014-2015)
Lambrinou Ekaterini	<p>Nothing to be declared (2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : Consultancy, AHF Academy. (2014) - Novartis : Consultancy, AHF Academy. Honorarium, Novartis-supported Satellite Symposium at EuroHeartCare 2015. (2015)
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Heart Failure (2013) - Abbott : MitraClip (2013) - Menarini : nebivolol (2014) - St Jude Medical : Heart Failure (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astrazeneca : Dyslipidemia (2013) - Boston Scientific : CRT (2014) - Servier : procoralan (2014) - Daiichi Sankyo : Teaching course on imaging (2015)

Guidelines on Pericardial Diseases 2015 (TF18) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lancellotti Patrizio	D - Research funding (departmental or institutional). - Actelion : Pulmonary Hypertension (2013)
Lazaros George	Nothing to be declared (2013-2014-2015)
Lehtonen Jukka	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra-Zeneca : Ischemic herat disease (2013-2014-2015)
Linhart Ales	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GlaxoSmithKline : Atherosclerosis (2013) - Servier : Arterial hypertension (2013-2014-2015) - Boehringer-Ingelheim : Arterial hypertension, atrial fibrillation (2013-2014-2015) - Merck Sharp & Dohme : Dyslipidemia (2013-2014-2015) - Bayer Schering Pharma : Dyslipidemia, pulmonary hypertension, atrial fibrillation (2013-2014-2015) - Shire HGT : Fabry disease (2013-2014-2015) - Genzyme : Fabry disease (2013-2014-2015) - Actelion : Pulmonary hypertension (2013-2014-2015) D - Research funding (departmental or institutional). - Shire HGT : Fabry disease (2014-2015)
Mascherbauer Julia	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - AOP Orphan Pharmaceuticals : pulmonary hypertension, heart failure (2013) - Novartis : heart failure (2013-2014) E - Research funding (personal). - Novartis : HFpEF (2015)
Meurin Philippe	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : ivabradine (2013-2014-2015)
Mirrakhimov Erkin	Nothing to be declared (2013-2014-2015)
Moller Jacob Eifer	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abiomed : Impella (2013-2014) - Novartis : Speaker fee (2013-2014)

Guidelines on Pericardial Diseases 2015 (TF18) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Moller Jacob Eifer	<ul style="list-style-type: none"> - Astra Zeneca : Speaker Fee, acute heart failure (2013-2014) - Orion : Levosimendan (2015) - Abiomed : Percutaneous mechanical support (2015)
Mueller Hajo	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Pfizer CH : Support of lunch (sandwiches) for CME meeting (echocardiography) in 2013 (2013) - Pfizer CH : Support of lunch (sandwiches) for CME meeting (echocardiography) in 2014 (2014) - Bayer AG : Support of lunch (sandwiches) for CME meeting (echocardiography) in 2014 (2015)
Nesukay Elena	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : cardiology (2013-2014-2015)
Nieman Koen	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Toshiba medical imaging : Computed tomography (2013) - Siemens Healthcare : Computed tomography (2013-2014-2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Bayer Healthcare : Contrast media (2013-2014-2015) - GE Healthcare : Contrast media (2014-2015) - Siemens Medical Solutions : Imaging (2014-2015)
Novo Salvatore	<p>Nothing to be declared (2015)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Phidea Group as Coordinator of the CAD Study : Ranolazine (2013) - MSD : Statins (2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Elirocumab (2013) - Bristol Myers Squibb : Apixaban (2014)
Pavlovic Milan	<p>Nothing to be declared (2013-2014-2015)</p>
Piepoli Massimo Francesco	<p>Nothing to be declared (2013-2014-2015)</p>

Guidelines on Pericardial Diseases 2015 (TF18) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Poder Pentti	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Cardiorentis : Acute Heart Failure (2013-2014-2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Cardiorentis : Acute Heart Failure (2014-2015)</p>
Price Susanna	<p>Nothing to be declared (2014-2015)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : educational contract (2013)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott : Mltraclip (2013)</p>
Rafnsson Arnar	<p>Nothing to be declared (2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : Fourier study (2014-2015)</p>
Rocha Lopes Luis	<p>Nothing to be declared (2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Genzyme : Fabry (2014-2015) - Health in Code SL : Genetics (2015) - Novartis : Oncology (cardio-oncology) (2015)</p>
Roos-Hesselink Jolien W	<p>Nothing to be declared (2013-2014-2015)</p>
Roubille Francois	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Coronary artery disease (2013-2014-2015) - Amgen Inc : Dyslipidemia (2013-2014-2015) - Merck Sharp & Dohme : dyslipidémie (2013-2014-2015) - Novartis : Heart Failure (2013-2014-2015) - Servier : Heart failure (2013-2014-2015) - Medtronic : Interventional Cardiology (2013-2014-2015)</p> <p>D - Research funding (departmental or institutional). - Astra Zeneca : Sleep apnea (2013-2014-2015)</p>

Guidelines on Pericardial Diseases 2015 (TF18) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Roubille Francois	<ul style="list-style-type: none"> - Daiichi Sankyo : Antiplatelet (2015) E - Research funding (personal). - Servier : Heart failure (2013)
Ruschitzka Frank	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Biotronik : Devices (2013) - Servier : Drugs (2013-2014-2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2013-2014-2015) - Novartis : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2013-2014-2015) - St Jude Medical : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2013-2014-2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Mars : Flavanol-like cocoa products (2013-2014-2015)
Sagrister Sauleda Jaime	Nothing to be declared (2013-2014-2015)
Samstad Stein Olav	Nothing to be declared (2013-2014-2015)
Schieffer Bernhard	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abiomed; Bayer, Astra Zeneca, : anticoagulants, mechanical heart support systems (2013-2014) - Abiomed; Bayer, Zoll : anticoagulants, life vest (2014) - Abiomed, Zoll, marquette, pfizer, bayer : Cardiogenic shock (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Deutsche Forschungsgemeinschaft : none (2013) - BMBF - German Ministry of Research and Education : none (2013) - Deutsche Herzstiftung : none (2013)
Separovic Hanzevacki Jadranka	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Ivabradin (2013) - Merck Sharp & Dohme : Zofenopril (2013) - Servier : Hypertension and CHF (norprexanil and ivabradin) (2014)

Guidelines on Pericardial Diseases 2015 (TF18) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Separovic Hanzevacki Jadranka	<ul style="list-style-type: none"> - Berlin Chemie AG : ACE inhibitor (2014-2015) - Genzyme : Fabry disease (2015) - Servier : Hypertension and CHF (norprexanil CCA and diuretic combinaton) (2015)
Shuka Naltin	Nothing to be declared (2013-2014-2015)
Shumavets Vadim	Nothing to be declared (2013-2014-2015)
Sisakian Hamayak	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Investigator, Speaker fee (2013) - Servier : Hypertension (2014) - Servier : Indapamide/Amlodipin (2015) - Bayer : Rivaroxaban (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Investigator (2013) - Servier : Indapamide/Amlodipin (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Yerevan State Medical University : No (2015)
Sousa Uva Miguel	Nothing to be declared (2013-2014-2015)
Stradins Peteris	Nothing to be declared (2013-2014-2015)
Van Camp Guy	Nothing to be declared (2013-2014-2015)
Vataman Eleonora	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Consultancy (2013) - Sanofi Aventis : Speaker fee (2013) - GEdeon Rihter : Speaker fee (2013) - Egis Pharma : consultancy (2014) - Servier : speaker (2014)

Guidelines on Pericardial Diseases 2015 (TF18) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Vataman Eleonora	<ul style="list-style-type: none"> - Sanofi Aventis : speaker (2014) - Berlin Chemie AG : speaker (2014) - Promed : speaker (2014-2015) - Krka Pharma : Consultancy (2015) - Gedeon Rrigter : Consultancy (2015) - Egis Pharma : scientific collaboration (2015)
Voigt Jens-Uwe	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - GE Healthcare : Ultrasound (2013-2014-2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Hitachi-Aloka : Ultrasound (2013) - Philips : Ultrasound (2013-2014) - GE Healthcare : Ultrasound (2013-2014) - Toshiba medical imaging : Ultrasound (2013-2014)
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichii : Atrial Fib (2013) - Merck Sharp & Dohme : Lipid Lowering (2013) - Philips : 3D echo (2014) - Toshiba medical imaging : fusion imaging 3D echo CT (2014) - Astra Zeneca : Speaker fee for 1 talk in 2014 (2014) - MSD : CV risk factors (2014-2015) - Abbott : Lecturing (2015) - Astra Zeneca : Lecturing (2015) - Pfizer : Lecturing (2015) - Sorin Group : Respicardia echo protocol (2015)

Guidelines on Pericardial Diseases 2015 (TF18) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - European Research FP7 : CV Imaging (2013) - Servier : Imaging in ISchemic patients (2013) - Siemens Healthcare : 3d echo software and free style echo (2014-2015) - Toshiba medical imaging : Fusion Imaging (2015) <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Springer : ESC Textbook of CV Imaging (2013) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Amgen : Clinical trial (2014-2015) - Novartis : Clinical trial (2014-2015) - Ikaria : Clinical trial (2014-2015)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>Nothing to be declared (2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antithrombotics (2014) - Sanofi Aventis : Hyperlipidemia (2014) - Boehringer-Ingelheim : Oral anticoagulation (2014) - Pfizer/BMS alliance : Oral anticoagulation (2014) - Novartis : Hypertension (2014-2015) - Bayer Healthcare : Oral anticoagulation (2014-2015) - Merck Sharp & Dohme : Antithrombotics (2015)
Achenbach Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation (2013) - Behring : Anticoagulation (2013) - Astra Zeneca : Antiplatelet Therapy (2013) - Abbott : Coronary Intervention (2013) - Siemens Healthcare : CT (2013) - Servier : Imaging (2013) - Guerbet : Imaging (2013) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Abbott : Coronary Intervention (2013-2014) - Siemens Healthcare : Imaging (2013-2015)
Agewall Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Böhringer Ingelheim : Anticoagulatn treatment (2013) - Roche Diagnostics : Cardiac markers (2013) - Orion : Heart failure (2013)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Agewall Stefan	<ul style="list-style-type: none"> - Pfizer : Lipids (2013) - Sanofi Aventis : Lipids (2013) - Siemens Healthcare : Markers (2013) - Astra Zeneca : Platelet inhibition (2013-2014-2015) - Thermo Fischer Scientific : Cardiac markers (2014-2015)
Badimon Lina	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : cardiovascular (2013) - Sanofi Aventis : cardiovascular (2013) - MSD-España : Lipids (2014) - Sanofi Aventis : lipids (2014-2015) - Burson Masteller : nutrition (2014-2015) - Astra Zeneca : thrombosis (2014-2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Astrazeneca : thrombosis (2014-2015)
Baron Esquivias Gonzalo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation (2013-2014-2015) - Boehringer-Ingelheim : Anticoagulation (2013-2014-2015) - Daiichi Sankyo : Anticoagulation (2013-2014-2015) - Pfizer : Anticoagulation (2013-2014-2015) - Menarini : Ischemic disease (2015) - Laboratorios Rovi : Ivabradine (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Biotronik : Vasovagal syncope & Pacing (2013) - Bayer : Anticoagulation (2015)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2013-2014-2015) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014-2015) - Abbott : transcatheter mitral valve repair (Mitraclip) (2013-2014-2015) - Edwards Lifesciences : transcatheter valve implantation (2013-2014-2015) - Direct Flow Medical : transcatheter valve implantation (2013-2014-2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : Bosentan for PAH treatment in congenital heart disease (2013-2014-2015) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014-2015) - Abbott : transcatheter mitral valve repair (Mitraclip) (2013-2014-2015) - Edwards Lifesciences : transcatheter valve implantation (2013-2014-2015) - Direct Flow Medical : transcatheter valve implantation (2013-2014-2015)
Bax Jeroen	<p>Nothing to be declared (2014-2015)</p> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Servier : Farma (2013) - Edwards Lifesciences : Heart Valves (2013) - GE Healthcare : Imaging (2013) - Lantheus Inc : Imaging (2013) - Boston Scientific : Pacing (2013) - Medtronic : Pacing (2013) - St Jude Medical : Pacing (2013) - Biotronik : Pacing (2013)
Bueno Hector	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - BMS/Pfizer : Apixaban (2013)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> - Roche Pharma : Dalcetrapib (2013) - Novartis : Relaxin (2013) - Bayer Healthcare : Aspirin, rivaroxaban (2013-2014-2015) - Sanofi Aventis : Clopidogrel (2013-2014-2015) - Daiichi Sankyo : Prasugrel (2013-2014-2015) - Eli Lilly : Prasugrel (2013-2014-2015) - Astra Zeneca : Ticagrelor (2013-2014-2015) - Novartis : Serelaxin (2014) - Pfizer : Apixaban (2014-2015) - Bristol Myers Squibb : Apixaban (2014-2015) - Servier : ivabradine (2014-2015) - Menarini : Ranolazine (2014-2015) - Abbott : Absorb stent (2015) - Novartis : Serelaxin, ACZ696 (2015) - Ferrer Internacional : Trinomia (polypill) (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2013-2014-2015)
Carerj Scipione	Nothing to be declared (2013-2014-2015)
Erol Cetin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Hypertension (2013-2014-2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Menarini : Hypertension (2013-2014-2015)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Fitzsimons Donna	Nothing to be declared (2013-2015) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : FH Treatment options (2014)
Gaemperli Oliver	Nothing to be declared (2013) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biosensors : Stents (2014) - Biosensors : Axxess Bifurcation Stent (2015) - Abbott Vascular : MitraClip (2015) - Biosensors : Travel Grant to AsiaPCR 2015 (2015)
Kirchhof Paulus	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2013) - Boehringer-Ingelheim : cardiovascular (2013-2014-2015) - Daiichi Sankyo : cardiovascular (2013-2014-2015) - Medtronic : cardiovascular (2013-2014-2015) - Pfizer : cardiovascular (2013-2014-2015) - St Jude Medical : cardiovascular (2013-2014-2015) - Sanofi Aventis : cardiovascular (2013-2014-2015) - Meda pharma : cardiovascular (2013-2014-2015) - Bristol Myers Squibb : cardiovascular (2013-2014-2015) - Merck Sharp & Dohme : cardiovascular (2013-2014-2015) - Medscape : cardiovascular (2014-2015) - Bayer Healthcare : cardiovascular (2015) - Correvio : cardiovascular (2015) - Remedica : cardiovascular (2015)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : cardiovascular (2013) - Bayer Healthcare : cardiovascular (2013) - Gilead : cardiovascular (2013) - BMS / Pfizer alliance : cardiovascular (2013) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - St Jude Medical : cardiovascular (2013-2014-2015) - Sanofi Aventis : cardiovascular (2013-2014-2015) - Meda pharma : cardiovascular (2013-2014-2015) - Daiichi Sankyo : cardiovascular (2014-2015) - British Heart Foundation : cardiovascular (2014-2015) - BMS / Pfizer alliance : cardiovascular (2014-2015) - Leducq Foundation : cardiovascular (2014-2015) - European Union FP7 : cardiovascular (2014-2015) - European Union horizon2020 : cardiovascular (2014-2015) - German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015)
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - B.Braun : Surgical instruments (2013-2014) - Astra Zeneca : Antiplatelet agents (2013-2014-2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - St Jude Medical : Cardiac valves (2013) - Boston Scientific : Coronary stents (2013) - Siemens Healthcare : Medical imaging (2013) - Johnson & Johnson : Thoracoscopic devices (2013)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kolh Philippe H	<ul style="list-style-type: none"> - Edwards Lifesciences : Cardiac valves (2013-2014-2015) - Medtronic : Cardiac valves (2013-2014-2015)
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Heart Failure (2013) - Abbott : MitraClip (2013) - Menarini : nebivolol (2014) - St Jude Medical : Heart Failure (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astrazeneca : Dyslipidemia (2013) - Boston Scientific : CRT (2014) - Servier : procoralan (2014) - Daiichi Sankyo : Teaching course on imaging (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Actelion : Pulmonary Hypertension (2013)
Lip Gregory Y H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astellas : atrial fibrillation, thrombosis (2013) - Biotronik : atrial fibrillation (2013-2014-2015) - Boehringer-Ingelheim : atrial fibrillation, thrombosis (2013-2014-2015) - Daiichi Sankyo : atrial fibrillation, thrombosis (2013-2014-2015) - Pfizer : atrial fibrillation, thrombosis (2013-2014-2015) - Bayer Healthcare : atrial fibrillation, thrombosis (2013-2014-2015) - Bristol Myers Squibb : atrial fibrillation, thrombosis (2013-2014-2015) - Medtronic : atrial fibrillation (2014-2015) - Roche Diagnostics : anticoagulation (2015)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lip Gregory Y H	D - Research funding (departmental or institutional). - Bayer : atrial fibrillation, thrombosis (2013) - Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)
Nihoyannopoulos Petros	Nothing to be declared (2014-2015) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GSK : Consultant for Imaging studies (2013)
Piepoli Massimo Francesco	Nothing to be declared (2013-2014-2015)
Ponikowski Piotr	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : anticoagulant (2013) - Bristol Myers Squibb : anticoagulant (2013) - ROSCHE : diabetes (2013) - Boehringer-Ingelheim : anticoagulant (2013-2014) - Respicardia : anticoagulant (2013-2014) - Johnson & Johnson : heart failure (2013-2014) - Pfizer : heart failure, anticoagulant (2013-2014) - Abbott Vascular : devices (2013-2014-2015) - Novartis : heart failure (2013-2014-2015) - Cardioentis : heart failure (2013-2014-2015) - Bayer Healthcare : heart failure (2013-2014-2015) - Vifor Pharma ltd : heart failure (2013-2014-2015) - CIBIEM : heart failure (2013-2014-2015) - Servier : heart failure, coronary artery disease (2013-2014-2015) - Amgen : heart failure, lipids (2013-2014-2015) - MSD : lipids (2014)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> - Astra Zeneca : acute coronary syndrome (2014-2015) - Boehringer-Ingelheim : anticoagulant, diabetes (2015) - Respicardia : devices (2015) - BioControl : devices (2015) - DC Device : devices (2015) - Celladon : heart failure (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Vifor Pharma ltd : heart failure (2014) - MSD : lipids (2014) - Astra Zeneca : acute coronary syndrome (2014-2015) - Respicardia : anticoagulant (2014-2015) - Novartis : heart failure (2014-2015) - Cardiorentis : heart failure (2014-2015) - Bayer Healthcare : heart failure (2014-2015) - CIBIEM : heart failure (2014-2015) - Servier : heart failure, coronary artery disease (2014-2015) - Amgen : heart failure, lipids (2014-2015) - BioControl : devices (2015) - DC Device : devices (2015) - Celladon : heart failure (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Vifor Pharma ltd : heart failure (2013) - Singulex : biomarkers (2015)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Roffi Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : antiplatelet therapy (2013) - Lilly : antiplatelet therapy (2013) - Astra Zeneca : antiplatelet therapy (2013) - Johnson & Johnson : coronary catheters (2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Biosensors : devices (2013-2014-2015) - Boston Scientific : devices (2013-2014-2015) - Medtronic : devices (2013-2014-2015) - Biotronik : devices (2013-2014-2015) - Abbott Vascular : devices (2013-2014-2015)
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Pulmonary arterial hypertension (2013-2014-2015) - GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2013-2014-2015) - Lilly : pulmonary arterial hypertension - ambrisentan (2013-2014-2015) - Actelion : pulmonary arterial hypertension - macitentan, selexipag (2013-2014-2015) - Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat, VTE - xarelto (2013-2014-2015) - AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Pulmonary hypertension (2013-2014-2015)
Vaz Carneiro Antonio	<p>Nothing to be declared (2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - AbbVie : Oncology (2013-2014)
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet drug (2013) - Eli Lilly : Antiplatelet drug (2013)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> - Abbott : Stent (2013) - Medtronic : Stent (2013) - Biotronik : Stent (2013) - Astra Zeneca : Antiplatelet therapy (2014-2015) - Eli Lilly : Antiplatelet therapy (2014-2015) - Bayer Healthcare : Antithrombotic drug (2014-2015) - Abbott : Stent and Heartvalvetherapy (2014-2015) - Biosensors : Stents (2014-2015) - Boston Scientific : Stents (2014-2015) - Medtronic : TAVI, Stent (2015) - Edwards Lifesciences : Transcatheter heart valves (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - St Jude Medical : OCT (2013-2014-2015) - Biotronik : Stent (2013-2014-2015) - Medtronic : Stent and Heartvalves (2014) - Medicines Company : Antithrombotic therapy (2014-2015) - Johnson & Johnson : Catheters (2014-2015) - Edwards Lifesciences : Heartvalves (2014-2015) - Abbott : Stent (2014-2015) - Boston Scientific : Stent and Heartvalves (2014-2015)
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichii : Atrial Fib (2013) - Merck Sharp & Dohme : Lipid Lowering (2013)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<ul style="list-style-type: none"> - Philips : 3D echo (2014) - Toshiba medical imaging : fusion imaging 3D echo CT (2014) - Astra Zeneca : Speaker fee for 1 talk in 2014 (2014) - MSD : CV risk factors (2014-2015) - Abbott : Lecturing (2015) - Astra Zeneca : Lecturing (2015) - Pfizer : Lecturing (2015) - Sorin Group : Respicardia echo protocol (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - European Research FP7 : CV Imaging (2013) - Servier : Imaging in ISchemic patients (2013) - Siemens Healthcare : 3d echo software and free style echo (2014-2015) - Toshiba medical imaging : Fusion Imaging (2015) <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Springer : ESC Textbook of CV Imaging (2013) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Amgen : Clinical trial (2014-2015) - Novartis : Clinical trial (2014-2015) - Ikaria : Clinical trial (2014-2015)